373
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country

ORCID Icon, , , , , , , & show all
Pages 1514-1517 | Received 13 Oct 2020, Accepted 12 Dec 2020, Published online: 15 Jan 2021
 

Ethical approval

The Institutional ethics committee approved the study in its present format.

Patient consent

Informed consent was taken from all the patients for participation in a study/report. Additional consent was taken from all patients for off label use of Venetoclax, as it is not yet approved for treatment of AML in India.

Author contributions

Jayastu Senapati and Tulika Seth designed the study, performed the research, analyzed the data and wrote the manuscript. Manoranjan Mahapatra analyzed the data and edited the manuscript. Rishi Dhawan, Pradeep Kumar, Mukul Aggarwal, Jasmita Dass, Ganesh Kumar Vishwanathan and Seema Tyagi edited the manuscript.

Disclosure statement

The authors declare no conflict of interest.

Data availability statement

Data available within the article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.